Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.71 |
| ▸ | CA9 | Q16790 | 1/20 | 0.71 |
| ▸ | TRIM24 | O15164 | 2/20 | 0.55 |
| ▸ | TRIM33 | Q9UPN9 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | FKBP4 | Q02790 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2562226 | 1.00 | CA1 (0.71) | CA1CA9TRIM24TRIM33ALDH1A1 | |
| Cyclohexanone SCHEMBL9561320 | 1.00 | CA1 (0.71) | CA1CA9TRIM24TRIM33ALDH1A1 | |
| SCHEMBL6201351 | 0.98 | CA1 (0.68) | CA1CA9TRIM24TRIM33ALDH1A1 | |
| SCHEMBL3324936 | 0.97 | CA1 (0.75) | CA1CA9TRIM24TRIM33ALDH1A1 | |
| Cyclopentanone SCHEMBL3628580 | 0.97 | CA1 (0.75) | CA1CA9TRIM24TRIM33ALDH1A1 | |
| SCHEMBL13317121 | 0.95 | CA1 (0.80) | CA1CA9TRIM24TRIM33ALDH1A1 | |
| SCHEMBL15141411 | 0.95 | CA1 (0.80) | CA1CA9TRIM24TRIM33ALDH1A1 | |
| SCHEMBL17515063 | 0.95 | CA1 (0.80) | CA1CA9TRIM24TRIM33ALDH1A1 | |
| Cyclohexanone SCHEMBL2324675 | 0.95 | CA1 (0.80) | CA1CA9TRIM24TRIM33ALDH1A1 | |
| SCHEMBL5243566 | 0.95 | CA1 (0.80) | CA1CA9TRIM24TRIM33ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3649183-A1 | SILICONE COMPOUNDS | The Procter and Gamble Company (US) | 2020-05-13 | — | — | EP | claimed |
| EP-3649184-A1 | SILICONE COMPOUNDS | The Procter and Gamble Company (US) | 2020-05-13 | — | — | EP | claimed |
| WO-2019010265-A1 | SILICONE COMPOUNDS | THE PROCTER & GAMBLE COMPANY (US) | 2019-01-10 | — | — | WO | claimed |
| WO-2019010263-A1 | SILICONE COMPOUNDS | THE PROCTER & GAMBLE COMPANY (US) | 2019-01-10 | — | — | WO | claimed |
| US-20190010427-A1 | SILICONE COMPOUNDS | THE PROCTER & GAMBLE COMPANY | 2019-01-10 | — | — | US | claimed |
| US-20190010293-A1 | SILICONE COMPOUNDS | THE PROCTER & GAMBLE COMPANY | 2019-01-10 | — | — | US | claimed |
| WO-2018145219-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING ADDICTIONS BY MEANS OF AVERSIVE COUNTERCONDITIONING | SERANI MOSTAZAL JORGE (CL) | 2018-08-16 | — | — | WO | claimed |
| EP-3197510-A1 | DELIVERY SYSTEMS COMPRISING MALODOR REDUCTION COMPOSITIONS | The Procter & Gamble Company (US) | 2017-08-02 | — | — | EP | claimed |
| EP-3149135-A2 | PERFUME COMPOSITIONS | Givaudan S.A. (CH) | 2017-04-05 | — | — | EP | claimed |
| WO-2016049458-A1 | DELIVERY SYSTEMS COMPRISING MALODOR REDUCTION COMPOSITIONS | THE PROCTER & GAMBLE COMPANY (US) | 2016-03-31 | — | — | WO | claimed |
| WO-2015181257-A2 | PERFUME COMPOSITIONS | GIVAUDAN SA (CH) | 2015-12-03 | — | — | WO | claimed |
| EP-2723315-A2 | USE OF SILICONE ELASTOMERS IN COSMETIC PREPARATIONS | Beiersdorf AG (DE) | 2014-04-30 | — | — | EP | claimed |
| WO-2013000742-A2 | USE OF SILICONE ELASTOMERS IN COSMETIC PREPARATIONS | BEIERSDORF AG (DE) | 2013-01-03 | — | — | WO | claimed |
| WO-2011101181-A1 | PERFUME COMPOSITIONS | HENKEL AG & CO. KGAA (DE) | 2011-08-25 | — | — | WO | claimed |
| EP-4686757-A1 | INHIBITORS OF EXPRESSION AND/OR FUNCTION | e-therapeutics PLC (GB) | 2026-02-04 | — | — | EP | disclosed |
| US-20250057747-A1 | ORGANIC COMPOUNDS AS FRAGRANCE | GIVAUDAN SA (CH) | 2025-02-20 | — | — | US | disclosed |
| EP-4437072-A1 | ORGANIC COMPOUNDS AS FRAGRANCE | Givaudan SA (CH) | 2024-10-02 | — | — | EP | disclosed |
| EP-0128175-A1 | TRICYCLO AD5,2,1,0?2,6 BDDECAN DERIVATIVES WITH FUNCTIONALIZED LATERAL CHAIN, PRODUCTION AND UTILIZATION THEREOF AS PERFUMES | Dragoco Gerberding & Co. GmbH (DE) | 1984-12-19 | — | — | EP | disclosed |
| WO-1984002338-A1 | TRICYCLO AD5,2,1,02,6 BDDECAN DERIVATIVES WITH FUNCTIONALIZED LATERAL CHAIN, PRODUCTION AND UTILIZATION THEREOF AS PERFUMES | DRAGOCO GERBERDING CO GMBH (DE) | 1984-06-21 | — | — | WO | disclosed |
| EP-0098367-A2 | Process for preparing macrocyclic ketol actones | HÜLS AKTIENGESELLSCHAFT (DE) | 1984-01-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250057747-A1 | ORGANIC COMPOUNDS AS FRAGRANCE | OPRK1, MAFK, OPRM1 | CA1 3516/4885CA9 2952/4885TRIM24 1508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.